Skip to content
1st Counsel – Lifestyle
Author:
NewcelX Ltd.
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
July 31, 2026
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
July 15, 2026
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
July 8, 2026
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
July 1, 2026